Buscar resultados de ensayos clínicos
Noonan Syndrome - 30 Studies Found
Estado | Estudiar |
Active, not recruiting |
Nombre del estudio: Sensitivity Study of Diagnostic for Early Detection of Dengue Infection Condición: Infectious Diseases Fecha: 2014-02-07 |
Completed |
Nombre del estudio: Specificity Study of Diagnostic for Early Detection of Dengue Infection Condición: Infectious Diseases Fecha: 2014-04-04 |
Completed |
Nombre del estudio: Observational Prospective Study on Patients Treated With Norditropin® Condición:
|
Recruiting |
Nombre del estudio: Familial Investigations of Childhood Cancer Predisposition Condición:
|
Completed |
Nombre del estudio: Laboratory Diagnosis and Prognosis of Severe Dengue Condición: Dengue Fever Fecha: 2011-08-22 |
Completed |
Nombre del estudio: Effect of MAXOMAT ® on the Growth of Small Children to NOONAN's Syndrome Condición: Noonan Syndrome Fecha: 2007-03-23 Intervenciones: Drug: MAXOMAT ®, biosynthetic growth hormone 2 posologies according to age (children and adolescent |
Recruiting |
Nombre del estudio: Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome Condición: Noonan Syndrome Fecha: 2016-03-09 Intervenciones:
|
Terminated |
Nombre del estudio: Research Study Using Recombinant Human Insulin-Like Growth Factor-1/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 for Children With Noonan Syndrome Condición: Noonan Syndrome Fecha: 2006-07-11 Intervenciones: Drug: rhIGF-1/rhIGFBP-3 |
Completed |
Nombre del estudio: Somatropin Effect on Linear Growth and Final Height in Subjects With Noonan Syndrome Condición:
Fecha: 2012-01-02 Intervenciones: Drug: somatropin Retrospective data collection based on data obtained from a prospective, open-label, ra |
Active, not recruiting |
Nombre del estudio: Investigating the Long-term Efficacy and Safety of Two Doses of NN-220 (Somatropin) in Short Stature Due to Noonan Syndrome Condición:
Fecha: 2013-08-20 Intervenciones: Drug: somatropin Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 |